Defending A Controversial Deal
30:29–31:37 · 69s
Waters CEO Udit Batra outlines why acquiring BD’s units fits their regulated, high-volume model and how synergies in biologics and microbiology are driving results.
30:29–31:37 · 69s
Waters CEO Udit Batra outlines why acquiring BD’s units fits their regulated, high-volume model and how synergies in biologics and microbiology are driving results.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.